Corcept Therap Drug Patent Portfolio
Corcept Therap's Family Patents
Clinical Trials
Recent Clinical Trials by Corcept Therap:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | Corcept Therapeutics | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | Corcept Therapeutics | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | Corcept Therapeutics | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | Corcept Therapeutics | NA |
TERMINATED
(Apr 1, 2026)
| PHASE1, PHASE2 |
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List